Patienter, som udviklede antistoffer over for infliximab, havde større sandsynlighed (cirka 2- 3 gange) for at udvikle infusionsrelaterede reaktioner.
Patients who developed antibodies to infliximab were more likely (approximately 2- 3 fold) to develop infusion-related reactions.